⚠ Evidence note: Exercise has the strongest human evidence base in this vault, but protocol-level specifics are far less settled than the headline benefit.
RANK-Ligand Inhibition (Denosumab) for Sarcopenia
Current understanding
Denosumab, an approved anti-RANKL monoclonal antibody used for osteoporosis, is being tested as a pharmacologic intervention for sarcopenia in older adults with coexisting osteoporosis, on the mechanistic rationale that RANKL signaling operates in the bone-muscle unit and may contribute to age-related muscle loss (mechanism-plausible). A randomized, double-blind, double-dummy active-controlled trial is underway; no muscle outcome readouts are available yet, so the human clinical case rests on a registered protocol (expert-opinion) rather than efficacy data.
Evidence log
- 2026-09-16 — RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: Pragmatic randomized, double-blind, active-controlled trial protocol (no readout) will test RANKL inhibition specifically for sarcopenia in post–hip-fracture patients, extending the denosumab-class bone-drug-repurposing case from osteoporosis-only sarcopenia into an acute surgical/fracture population where muscle loss and mortality are both high. [expert-opinion] (novelty: 3)
- 2026-09-18 — RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: cross-connection with mechanical-loading-aged-bone: Both target the bone-muscle unit: denosumab is an approved osteoporosis drug being extended to muscle endpoints, connecting bone-loading biology to sarcopenia intervention research. (novelty: 3)
Open questions
Related
Contributing findings
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
18-sep-2026
novelty 3
per-area 3
introduces
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
16-sep-2026
novelty 3
per-area 3
strengthens